Back to top

Lexicon announces presents data from Phase 2 PROGRESS study for pilavapadin

Lexicon (LXRX) Pharmaceuticals announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its investigational, AAK1...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Lexicon Pharmaceuticals, Inc. (LXRX)